Web Toolbar by Wibiya
Login | Sign Up AnonymousUser
twiter
New to Comunitee?


or Sign Up with Email

Health

>> AMGEN Latest News

MAY 22, 2015 - Reuters

A Must Read - Share

Amgen ends partnership with AstraZeneca on psoriasis drug

(Reuters) - Amgen Inc said it will terminate a collaboration with AstraZeneca Plc to develop a psoriasis drug after it observed suicidal thoughts in the subjects of a trial.

Tags: Amgen ends partnership with AstraZeneca on psoriasis drug,  Amgen Latest News

MAY 22, 2015 - Wall Street Journal

A Must Read - Share

Amgen Ends Psoriasis-Drug Partnership With AstraZeneca

Amgen Inc. said it is no longer working with AstraZeneca PLC on the co-development of brodalumab, a treatment for conditions including psoriasis, due to safety concerns.

Tags: Amgen Ends Psoriasis-Drug Partnership With AstraZeneca,  Amgen Latest News

MAY 22, 2015 - Yahoo! News

A Must Read - Share

Amgen ends partnership with AstraZeneca on inflammation drug

(Reuters) - Amgen Inc said it will terminate a collaboration with AstraZeneca Plc to develop an inflammation drug after it observed suicidal thoughts in the subjects of a trial. AstraZeneca could decide on the development and marketing of the drug for all territories, except for Japan and certain Asian territories, where Kyowa Hakko Kirin has the rights to it, Amgen ...

Tags: Amgen ends partnership with AstraZeneca on inflammation drug,  Amgen Latest News

MAY 22, 2015 - Yahoo! News

A Must Read - Share

Amgen first to win EU backing for new kind of cholesterol drug

(Reuters) - Amgen Inc's closely watched new cholesterol drug, Repatha, has been recommended for approval in Europe, putting the U.S. drugmaker ahead in a race with rival Sanofi SA. Repatha, or evolocumab, belongs to a new class of cholesterol-lowering drugs known as PCSK9 inhibitors that have the potential to drastically reduce the risk of heart attacks when used in addition to standard ...

Tags: Amgen first to win EU backing for new kind of cholesterol drug,  Amgen Latest News

MAY 19, 2015 - Yahoo! News

A Must Read - Share

Amgen cholesterol drug could get EU green light this week

By Ben Hirschler LONDON (Reuters) - Amgen's new cholesterol drug Repatha could be recommended for approval in Europe as early as this week, putting it ahead in a race with a rival product from Sanofi. Repatha, or evolocumab, belongs to a new class of cholesterol-lowering drugs known as PCSK9 inhibitors that clinical trials suggest may slash the risks of heart ...

Tags: Amgen cholesterol drug could get EU green light this week,  Amgen Latest News